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A mutation in p53 is frequently reported in nearly 50% of all of human cancers arising from DNA-binding 
core domain of p53. DNA-contact mutant R273H rendered p53 at dysfunctional state due to the substitution 
of single residue Arg273 for His273. Here, natural bioactive compounds curcumin, alpinetin and 
flavokawain B were investigated for possible stabilisation of wild-type p53 expression in vitro using 
HT-29 cells harbouring R273H rendered p53. Accordingly, all the bioactive compounds were able to 
induce the expression of wild-type p53 both at the levels of gene and protein expression.  A dose-
dependent induction of p53 was evident at 12.5, 25 and 50 µM concentration. The present study has 
shown that the bioactive compounds may have restored the wild-type p53 functional activity in tumour cells 
expressing R273H mutant p53. 
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INTRODUCTION 
The p53 is a tumour-suppressor protein critical for 
preventing cancer growth via transcriptional 
regulation of target genes associated with DNA 
repair, cell cycle checkpoints as well as apoptosis 
(Blandino and Agostino, 2018; Malami et al., 
2017). In response to numerous stress signals, 
p53 is activated leading to a series of diverse 
anti-proliferative responses (Fridman and Lowe, 
2003). Under normal conditions,  the function of 
p53 is effectively regulated through the 
overexpression of human murine double minute 
2 (MDM2) (Zhao et al., 2015). A mutation in p53 
gene has been implicated in several tumours 
including colorectal cancer (Joerger and Fersht, 
2016). A mutation in the wild-type p53, 
consequently rendered p53 dysfunctional by failure 
to perform similar wild-type functions in executing 
transcriptional regulation of target genes that 
prevent cancer progression (Vijayakumaran et al., 
2015). Consequently, mutant p53 protein becomes 
unsusceptible to MDM2 degradation, which 
accumulates in cancer cells and enhances 
oncogenic functions (Bykov et al., 2005).  
Approximately, 50% of all of human cancers are 
reported to contain p53 mutations arising from 
DNA-binding core domain of p53, thereby 
disrupting the protein-DNA interaction (Tan et al., 
2015). DNA-contact mutant R273H rendered p53 
at dysfunctional state resulting from substitution of 
single amino acid residue arginine for histidine at 
position 273 (Malami et al., 2017). We have 
recently reported a probable mechanistic study for 
possible restoration of wild-type p53 functional 
activities by small molecular weight natural 
products curcumin, alpinetin, and flavokawain B 
(Figure 1) using In Silico studies (Malami et al., 
2017). In the study, we have anticipated that these 
bioactive compounds are capable of mediating a 
direct p53 reactivation via specific interaction with 
DNA binding core domain of R273H mutant p53. 
The present study therefore investigates the 
possible in vitro reactivation of wild-type p53 
tumour-suppressor by the bioactive compounds; 
curcumin, alpinetin and flavokawain B in HT-29 























Figure 1: Chemical structure of (A) Curcumin; (B) 
Alpinetin; and (C) Flavokawain B. 
 
MATERIALS AND METHODS 
Cell Culture 
A Human HT-29 cells (ATCC) were retrieved 
frozen from a liquid nitrogen storage tank of 
MAKNA-Cancer Research Laboratory and 
maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Sigma-Aldrich, USA) containing 10% 
Fetal Bovine Serum (FBS) (PAA, Germany) and 
1% antibiotics (consist of 100 IU penicillin and 100 
µg/mL streptomycin) (Sigma-Aldrich, USA). All 
cells were constantly maintained at 37 °C inside a 
humidified incubator supplied with 5% CO2. Cell 
culture was maintained by routine harvesting of 
cells with the aid of 0.05% trypsin-EDTA at the 
level of 70–80% confluence. 
 
Preparation of Test Compounds 
Alpinetin and flavokawain B were previously 
isolated from the rhizome of Alpinia mutica Roxb 
(Malami et al., 2016) and used for the present 
study, whilst curcumin (CU) (purity 97.35%) was 
purchased from Sigma-Aldrich, USA. Stock 
solution for each compound was prepared at a 
concentration of 400 µM in DMSO (50 µL). Each 
calculated concentration contains 0.1% DMSO as 
the final concentration. Negative control was 
treated with 0.1% DMSO. 
Treatments 
HT-29 Colorectal cancer cells at a concentration of 
0.5 × 104 were cultured in 6-well plates and 
incubated for 24 h to allow full attachment. Cells 
were subsequently treated at different 
concentrations with either curcumin (12.5 µM, 25 
µM and 50 µM), alpinetin (12.5 µM, 25 µM and 50 
µM) or flavokawain B (12.5 µM, 25 µM and 50 
µM). Likewise, non-treated control cells were 
treated with 0.1% DMSO. 
 
RT-PCR Analysis of p53 mRNA 
Synthesis of cDNA from total RNA was performed 
using a RevertAid cDNA synthesis kit (Thermo 
Scientific, US) according to the manufacturer’s 
recommendations. Briefly, approximately 1.0 µg 
from total RNA, random hexamer, 5× reaction 
buffer, RNase inhibitor, 10 mM dNTP, and 
RevertAid were collectively mixed in 200 µL PCR 
tube. Total reaction volume was made to 20 µL 
with nuclease-free water, gently mixed, 
centrifuged, and incubated in DNA thermal cycler 
at 25 °C for 5 min followed by 42 °C for 60 min. 
The reaction was terminated at 70°C for 5 min and 
kept at 4 °C. A total of 20 µL reaction volume 
containing cDNA template was amplified using 
Exprime Taq premix (Genet Bio, Daejeon, Korea). 
The cDNA template was amplified for 5 min at 
94°C for one cycle, followed by 25 cycles for 30 
sec at 48°C, 30 sec at 47°C, 30 sec at 72°C, and 
final extension for 5 min at 72°C for one cycle. The 
p53 primer sequences used for PCR amplification 
are forward: 5’-TGTGGAGTATTTGGATGACA-3’ 
and reverse: 5’-GAACATGAGTTTTTTATGGC-3’. 
 
Extraction of Cell Lysate 
Treated and non-treated HT-29 cells were 
harvested using radioimmunoprecipitate assay 
(RIPA) buffer (Merck, Germany) supplemented 
with 10% protease inhibitor cocktail (Merck, 
Germany) and centrifuged at 20,000 ×g for 10 min 
at 4 °C using Eppendorf microcentrifuge 
(Eppendorf, Germany). Cell lysate was aliquoted in 
200 µL tubes and kept frozen in a −80 °C storage 
until use. Protein content in the lysate was 
quantified using the Bradford protein assay. 
 




Western Blot Analysis 
Briefly, 25 µg of protein sample was separated by 
PowerPacTM electrophoresis (Bio-rad, USA) on an 
SDS-polyacrylamide gel followed by transfer of the 
separated proteins into a Polyvinylidene difluoride 
membrane (PVDF) (Bio-rad, USA) using semi-dry 
transblot Turbo (Bio-rad, USA). The membrane 
was incubated at room temperature with gentle 
agitation in 5% non-fat dry milk (Bio-rad, USA) in 
Tris-buffered saline and Tween 20 (TBS-T). 
Membrane was washed for 3 consecutive times in 
TBS-T and incubated at room temperature for 2 h 
with either a labelled mouse anti-β-Actin (Santa 
Cruz, USA) or mouse anti-p53 (Biolegend, USA). 
Thereafter, the target protein was finally detected 
after labelling with horseradish peroxidase-
conjugated Goat anti-mouse IgG (Biolegend, US) 
using ECL chemiluminescence (Thermo Scientific, 
USA) in ChemiDoc (Bio-rad, USA). 
 
RESULTS 
In the present study, the bioactive compounds 
were examined for their potential to induce the 
wild-type p53 expression using HT-29 cell line 
known to express R273H mutant p53. HT-29 cells 
treated with either curcumin, alpinetin, or 
flavokawain B at different concentrations (12.5, 25 
and 50 µM) induced the expression of p53 mRNA 
when compared to HT-29 cells treated with DMSO 
used as a negative control. 
 
In Figure 2A and 2B, the expression levels of p53 
gene were drastically increased in cells treated 
with curcumin and alpinetin at 25 µM and 
subsequently decreased slightly at 50 µM. 
Whereas, the levels of p53 genes were expressed 
in a steady-state in the cells treated with 
flavokawain B at 12.5, 25 and 50 µM.  On the 
other hand, the expression of p53 protein in HT-29 
cells treated with curcumin at different 
concentrations was prominent at 25 and 50 µM 
when compared to the DMSO-treated control 
(Figure 2C). Likewise, a similar effect was 
sequentially visible in the presence of either 
alpinetin or flavokawain B (Figure 2D and 2E).  
 
DISCUSSION 
Amongst the hot spot mutation sites (Arg175, 
Gly245, Arg248, Arg249, Arg273, and Arg282) that 
are implicated in p53 mutation, DNA-contact 
mutant R273H has been one of the five frequently 
observed in all human cancers (Joerger et al., 
2006). DNA-contact mutant R273H is structurally 
classified under contact category of p53 mutation, 
which defines the direct interactions involving 
amino acid residues Arg248 and Arg273 and the 
DNA (Joerger et al., 2006). 
 
Therefore, any mutation in these residues will lead 
to loss of contact with the DNA-binding surface. 
Consequently, such mutation has displayed 
increased resistance to antitumor agents, including 
very significantly used cisplatin (Li et al., 2014). 
Hence, targeting p53 mutation have become a 
recent drug target for development of novel 
therapeutics for cancer treatment. 
 
In the present study, we tested and reported the 
effect of curcumin, alpinetin and flavokawain B on 
the wild-type p53 status in HT-29 cells harbouring 
R273H mutant p53. We examined the expression 
of wild-type p53 mRNA to ensure the expression of 
the appropriate gene in the treated cells. The 
expected length of the PCR product of p53 cDNA 
was produced, which conform the target wild-type 
p53 mRNA. Furthermore, we found that all the 
bioactive compounds were able to induce the level 
of wild-type p53 mRNA expression after 72 h 









Figure 2: (A) Levels of p53 mRNA expression in HT-29 cells following treatment with curcumin, alpinetin 
and flavokawain B; (B) Graphical representation of p53 gene expressed in HT-29 cells; (C); (D); and (E) 
shows the levels of p53 protein expression in HT-29 cells following treatment with curcumin; alpinetin; and 
flavokawain B, respectively; (F) Graphical representation of p53 protein expressed in HT-29 cells. CU: 
Curcumin; APN: alpinitin; FKB: flavokawain B; DL: DNA ladder; DC: DMSO treated control. All treatments 
are in µM concentration. Volume intensities of gel signals were analysed by GelAnalizer2010. 
 
In Western blotting, we found that wild-type p53 
protein levels were expressed in an unstable 
manner except for the cells treated with alpinetin. 
We noticed that the expression of wild-type p53 
protein is inconsistent with the level of p53 mRNA 
abundantly expressed in the cells. In Figure 2F, 
the subsequent decreased in the p53 protein after 
72 h treatment at 50 µM concentration of either 
curcumin or flavokawain B is likely due to the 
instability of wild-type p53 protein. At physiological 
temperature, p53 protein have a short half-life of 
approximately 9 min and melting temperature of 
approximately 44°C, thereby subjecting the protein 
to unstable conditions and subsequently suffer 
rapid protein denaturation (Boeckler et al., 2008). 
In response to alpinetin, the rate at which the cells 
retains the ability to sustain the p53 protein 
instability is not clear. Previously, treatment of 
cancer cells harbouring R273H mutant p53 with 
different agents have been reported to stabilised 
p53 activity by either restoring the wild-type p53 
activity resulting to its stabilisation (Bykov et al., 
 




2002a, 2005b; Tang et al., 2007; Zache et al., 
2008;; Lambert et al., 2009, 2010; Zhao et al., 
2010; Burmakin et al., 2013) or by restoring the 
sequence-specific DNA binding on the binding core 
domain of mutant p53 (Demma et al., 2010; 
Weinmann et al., 2008), or by downregulating the 
mutant p53 with minimal effect on the wild-type 
p53 (Li et al., 2011; Wang et al., 2011 ; 
Vakifahmetoglu-Norberg et al., 2013; Yi et al., 
2013; Yan et al., 2014; Alexandrova et al., 2015; 
Zhang et al., 2015). Either way, the present study 
has preliminarily shown that the bioactive 
compounds under investigation are capable of 
restoring p53 functional activity in tumour cells 




Findings from in vitro investigation strongly suggest 
the ability of curcumin, alpinetin and flavokawain B 
to influence R273 mutant p53, thereby causing 
direct expression of wide-type p53 protein 
essential in transactivation of target genes 
implicated in triggering cell cycle arrest and 
ultimately apoptosis induction.  
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